Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Breast cancer patient receiving AC regimen chemotherapy (Doxorubicin + Cyclophosphamide) who
has nausea score from 40/100 VAS or vomiting after the first or second cycle of chemotherapy
is recruited. The patient who meets the eligibility criteria and provides informed consent is
randomised to receive either Ginger capsule (500 mg) or placebo taking twice a day by mouth
during the first 5 days of chemotherapy cycle. The study drug will be switched on the
subsequent cycle (i.e. the patient who received Ginger capsule will receive placebo and vice
versa). The primary outcome is the nausea score and vomiting during the first 5 days of each
chemotherapy cycle when receiving the study drug.